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Abstract
Prognostic gene signatures like the wound and hypoxia signature
differ by assumptions of cellular growth. Although gene signatures
show little overlap, they also track within the group of luminal
breast tumours those with a high proliferation and poor prognosis.
Oxidative stress is another assumption of cellular growth. It affects
several pathological conditions through its influence on the
regulation of protein kinases and signal transduction pathways. A
comprehensive set of 62 core genes from cultured oestrogen- and
oestrogen receptor-deprived epithelial breast cancer cells is
responsive to three forms of oxidative stress. Evidence is
presented that oxidative stress involves the development of an
aggressive subset of primary oestrogen receptor-positive breast
tumours.
An imbalance between pro-oxidants and antioxidants can
lead to a state of oxidative stress. Yau and Benz [1] studied
the subset of oestrogen (E)-responsive genes susceptible to
modulation by oxidative stress. They identified an overlapping
set of 891 E-related and oestrogen receptor (ER)-related
probes in the MCF-7 ER+ breast cancer cell line associated
with loss of E and ERα function (E/ER signature). They
further compared the genes involved in this E/ER signature
with probes from two different MCF-7 cell lines modulated by
oxidative stress: (a) MCF-7 controls (Ox signature) and (b)
MCF-7 cell lines with ERα knockdown (Ox′ signature) leading
to, respectively, the Ox-E/ER signature and Ox′-E/ER
signature. The Ox-E/ER signature is a set of 62 unique
genes, 46 of which are connected within networks linked
through various kinases and growth factors (19) and oxidative
signalling (16) and cell motility (11) pathways. Some of the
genes in the signatures also imply, not surprisingly, that
oxidative stress is associated with an impaired tumour
necrosis factor-nuclear factor-kappa-B cell survival-death
pathway and variable endocrine responsiveness of ER+
breast tumours.
Only a third of genes involved in loss of ER function overlap
with E-induced genes in MCF-7 breast cancer cells [2],
which suggests that E withdrawal and ER function loss are
not entirely reciprocal conditions relative to E stimulation.
Only 8% of probes involved in ER function loss were affected
by all oxidants, including Bcl2 but not progesterone receptor
(PR) and GREB1, implying that PR loss is only a partial
surrogate for increased oxidative stress [3]. Although there is
little gene overlap with the prognostic molecular profile of
ER+/PR– tumours in the luminal B subset as defined by Perou
and colleagues [4] and Creighton and colleagues [5], these
findings confirm that oxidative stress may be intrinsic to the
highly proliferative subtype of luminal tumours [6]. Though
ER+, they may be functionally analogous to E-independent
breast tumours. They are also likely to show less sensitivity to
hormonal therapies. These observations are synergistic with
the known effects of oxidative stress in impairing ER
functions related to DNA binding and transactivation in up to
a third of ER+ breast tumours which correlated with loss of
PR expression and a tamoxifen-resistant phenotype [7,8].
In ER+ breast tumours, those with a high grade, those that
are PR–, HER-2+, and those with a higher expression of
proliferative genes as seen in young women were associated
with the oxidative stress gene signature. Increasing age at
breast cancer diagnosis was – surprisingly – not related to an
enrichment of oxidative stress markers, again showing
evidence that loss of PR with age is more than increased
oxidative stress, which has already been suggested by others
[9,10]. Our findings of an age-dependent association
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between HER-2 amplification and PR loss in ER+ tumours
might be explained by this biologic trait [11].
To ascertain the role of oxidative stress in breast cancer
prognosis, the authors associated the five derived gene
signatures and four other reported gene signatures,
including sustained E induction, luminal subtype, MAPK
(mitogen-activated protein kinase) induced/repressed, and
tumour proliferation studied with follow-up data in a pooled
set of 394 ER+ primary breast tumours. The poor clinical
outcome associated with the expression of the ‘Ox-E/ER’
signature in this manuscript is in agreement with previously
published work [6]. Also, an association between a
nonfunctioning NQO1 enzyme – which in normal
circumstances protects against oxidative stress – and an
adverse breast cancer outcome was recently described
[12]. We also know from the clinic that women with an ER+
breast tumour do worse if the tumour lacks PR or
overexpresses HER-2 [13,14]. That the gene signature
outperformed the prognostic model achieved by the PR
status alone may be related to several factors. We have
already suggested an age-related association between PR
loss and HER-2 overexpression in ER+ breast tumours [15]
and we suggest an interaction between oxidative stress, age
at breast cancer diagnosis, and PR expression. Yau and
Benz need to further explore whether their prognostic model
still outperforms the expression of PR as a prognostic
marker stratifying for age at diagnosis.
This study is a first look into the possible association between
oxidative stress, loss of ER function, PR expression, and poor
prognostic breast cancer phenotypes. Extending this concept
to other ER+ breast cancer cell lines with oxidising agents
would have strengthened this work tremendously but should
encourage others to explore this area. This gene list is far
from being a clinical test. Whether any of the tested
microarray gene expression profiling for breast cancer
prognosis is better than an optimised panel of clinical,
objectively measured, prognostic markers remains an open
question and currently is being explored in prospectively
designed clinical trials. Although the oxidative stress pheno-
type is associated with a poor disease outcome, Yau and
Benz did not address the effect of treatment data. Because
radiation and chemotherapy like anthracyclines influence
oxidative processes and DNA repair, accounting fortreatment
effects in any study design is a requirement. If oxygen radicals
do lead to a poorer prognosis, antioxidants like carotenoids
(for example, α-carotene,  β-carotene, lutein, zeaxanthin, β-
cryptoxanthin, and lycopene) and vitamins C and E may be of
therapeutic value, although such an approach does not seem
to work for ER+/PR– lesions [16,17]. This, however, remains
an exciting possibility also for PR+ lesions because well-
chosen antioxidants are of low toxicity.
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